Free Trial

Vivani Medical Q1 2023 Earnings Report

Vivani Medical logo
$1.18 0.00 (0.00%)
(As of 12/20/2024 05:31 PM ET)

Vivani Medical Earnings Headlines

Vivani begins exenatide implant trial for obesity in Australia
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Vivani Medical Reports Q3 Loss, Advances GLP-1 Trials
Vivani Medical Secures Funding for GLP-1 Implant Trial
See More Vivani Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email.

About Vivani Medical

Vivani Medical (NASDAQ:VANI), a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

View Vivani Medical Profile

More Earnings Resources from MarketBeat

Upcoming Earnings